ProQR Therapeutics shares surge 20.43% intraday as company announces investor webinar and Oppenheimer sets $9 price target.

lunes, 30 de marzo de 2026, 11:57 am ET1 min de lectura
PRQR--
ProQR Therapeutics surged 20.43% intraday, driven by the company's announcement of an investor webinar on April 8 to showcase its AX-0810 and RNA editing pipeline, along with a clinical data timeline for new projects. Additionally, Oppenheimer set a $9 price target for PRQR, rating it "Outperform" and indicating a 409.9% upside potential.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios